OnDosis announces commitment of 30 MSEK raise from owners and DIG Investment

Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, AstraZeneca Medtech spin-off OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.

Gothenburg, Sweden – September 11th.OnDosis today announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.

The commitment follows a successful signing of a strategic partnership agreement between OnDosis and Tiefenbacher Group. With the partnership and raise, OnDosis will be able to execute the near-term growth agenda; initially focusing on bringing OnDosis’ ADHD drug/device combination currently in development to the market in the US. This followed by potential initiation of several other drug/device combinations for diseases which require individual dosing and benefit from combining traditional drug-based therapies with digital therapeutics.

OnDosis is uniquely positioned in the convergence between personalized medicine and digital therapeutics. Based on the rapidly growing demand for personalizing medicine and applying digital technologies to healthcare delivery, OnDosis plan to raise additional funds in the coming year.

Martin Olovsson, CEO of OnDosis says: “We are excited to have continued support from current strategic owners, among them AstraZeneca and Boston Consulting Group, and a new financial investor, DIG Investment, to back our ambitious growth agenda. With the breakthrough agreement with Tiefenbacher Group, we will now accelerate in building critical team capabilities and conclude final steps in the development of our first product launch anticipated in the coming years.”

About OnDosis:

Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.

For more information, please contact:

Martin Olovsson, CEO OnDosis
Phone +46 76 772 85 01